CTLA4 and Hepatitis: Other immune checkpoint inhibitors (ICI), including the CTL-associated antigen 4 (CTLA-4) blockers ipilimumab and tremelimumab, are currently under evaluation for TNBC treatment in combination with other drugs (clinical trial identifiers: NCT03606967, NCT02983045); however, anti–CTLA-4 treatments induce severe side effects such as endocrinopathies, myopathy, enterocolitis, and hepatitis (16–19), which narrow their use.